ArticleExperimental biology and medicine (Maywood, N.J.)2020
Circulating serum exosomal miR-20b-5p and miR-3187-5p as efficient diagnostic biomarkers for early-stage non-small cell lung cancer.
Article in Experimental biology and medicine (Maywood, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Diagnostic value of exosomal noncoding RNA in lung cancer: a meta-analysis.Frontiers in oncology · 2024Pooled it
- Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.BMC medicine · 2022Pooled it
- Review
- [Mechanisms of Exosomes in Lung Cancer Bone Metastasis and Related Clinical Advances].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Extracellular vesicles in cancer immunotherapy: Therapeutic, challenges and clinical progress.Asian journal of pharmaceutical sciences · 2025Review
- Cell-free and extracellular vesicle microRNAs with clinical utility for solid tumors.Molecular oncology · 2025Review
- The NcRNA/Wnt axis in lung cancer: oncogenic mechanisms, remarkable indicators and therapeutic targets.Journal of translational medicine · 2025Review
- Diagnostic value of microRNA-200 expression in peripheral blood-derived extracellular vesicles in early-stage non-small cell lung cancer.Clinical and experimental medicine · 2024Article
- Circulating serum exosomes i-tRF-AspGTC and tRF-1-SerCGA as diagnostic indicators for non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Extracellular Vesicles and Exosomes: Novel Insights and Perspectives on Lung Cancer from Early Detection to Targeted Treatment.Biomedicines · 2024Review
- Serum extracellular vesicles 3'tRF-ThrCGTand 3'tRF-mtlleGAT combined with tumor markers can serve as minimally invasive diagnostic predictors for colorectal cancer.Frontiers in oncology · 2024Article
- Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts.Journal of experimental & clinical cancer research : CR · 2023Review
- Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients.Frontiers in oncology · 2023Review
- Emerging function and clinical significance of extracellular vesicle noncoding RNAs in lung cancer.Molecular therapy oncolytics · 2022Review
- Circulating exosomal miRNAs and cancer early diagnosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Tumor-derived exosomes: immune properties and clinical application in lung cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Fucosylated exosomal miRNAs as promising biomarkers for the diagnosis of early lung adenocarcinoma.Frontiers in oncology · 2022Article
- The emerging role of miR-20b in human cancer and other disorders: Pathophysiology and therapeutic implications.Frontiers in oncology · 2022Review
- Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer.Advanced drug delivery reviews · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
impact statementThe high mortality of non-small cell lung cancer (NSCLC) is mainly because the cancer has progressed to a more advanced stage before diagnosis. If NSCLC can be diagnosed at early stages, especially stage 0 or I, the overall survival rate will be largely improved by definitive treatment such as lobectomy. We herein validated two novel circulating serum ExmiRs as diagnostic biomarkers for early-stage NSCLC to fulfill the unmet medical need. Considering the number of specimens in this study, circulating serum exosomal miR-20b-5p and miR-3187-5p are putative NSCLC biomarkers, which need to be further investigated in a larger randomized controlled clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.